Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / November 16, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Renovacor, Inc. (NYSE:RCOR)'s ...
Solid Biosciences press release ( NASDAQ: SLDB ): Q3 Net loss for the third quarter of 2022 was $20.4 million Solid had $142.2 million in cash, cash equivalents and available-for-sale securities as of September 30, 2022, Research and development expenses for the thir...
- Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission - - Company ends Q3 with approximately $142.2 million in cash and investments; ant...
In a bid to comply with Nasdaq's minimum bid price requirement, Solid Biosciences ( NASDAQ: SLDB ) on Thursday has announced a 1-for-15 reverse split of its common stock. That means every fifteen shares of the company’s issued and outstanding common stock ...
- Effective at 5 pm ET October 27, 2022 - CHARLESTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will impleme...
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein data are also under evaluation and offer potential to improve safety and e...
- Stride velocity 95 th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural history patients - - SV95C is an objective, real-world assessment of ambulatory function measured by the ActiMyo weara...
Solid Biosciences ( NASDAQ: SLDB ) gained ~14% on Friday to post the best intraday gain since March after JPMorgan upgraded the clinical-stage biotech to Neutral from Underweight, citing its deal to acquire the privately held gene therapy company AavantiBio. Analysts...
Life sciences company Solid Biosciences ( NASDAQ: SLDB ) will acquire the gene therapy company AavantiBio. The combined entity aims to advance a portfolio of neuromuscular and cardiac programs. The merger is subject to an approval by the shareholders of Solid. Post...
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including product candidates for Duchenne mus...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...